Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

UCB SA Add to portfolio

N100:UCB, Jul 18, 11:52 UTC

Latest N100:UCB News

Filter your feed

Apply Filter

Monday, July 08


News

Taking The Irrefutable Step ::Ucb, The Belgium, (Euronext BE:UCB.BB)

UCB SAF

The last day ratio of the business at $74.92 with the difference of $-0.5, -0.67%, Loss (↓). 50-Days Moving Average (MA) recorded as: 70.268, (MA-50 is used by traders to gauge mid-term trends). A stochastic oscillator is a momentum indicator comparing a particular closing price of a security to a range of its prices over a certain period of time. The sensitivity of the oscillator to market movements is reducible by adjusting that time period or by taking a moving average of the result.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, July 03


News

Is Technical Outlook Good?:Montea C.V.A., The Belgium, (Euronext BE:MONT.BB) - Research On Mathematics

UCB

The Current & Previous Price Signals of Montea C.V.A., MONT.BB recorded as Current Price Signals “Buy”, while previous Price Signals was “Buy” with current percentage of “88%”, while previouse percentage was “64% . Sell signals can be generated through a variety of techniques. It is a technical and important part to determine a stock’s current value and predicting future price movement. Stochastic / Stochastic %K / Stochastic %D / True Rang (MONT.BB, Montea C.V.A.):.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, July 02


News

DEARhealth Announces Collaboration with UCB to Improve Care Delivery Through New Technology for Patients Living with Epilepsy

UCB

LOS ANGELES, July 2, 2019 /PRNewswire/ -- DEARhealth Inc., a software company focused on value-based disease management, today announced a collaboration with global biopharmaceutical leader UCB to improve care delivery for patients living with epilepsy. The collaboration will focus on improving patient experiences and their health outcomes with the hope of reducing the overall medical costs and is built on DEARhealth's software system to empower value-based disease management through Artificial Intelligence (AI) powered care pathways, integrated in the Electronic Medical Records (EMR). "We couldn't be more excited to partner with UCB at a time where care is transforming so rapidly. DEARhealth is collaborating with companies like UCB to share disease-specific knowledge and expertise in order to maximize value for patients and in epilepsy care," said Daniel Hommes, MD PhD and Chief Executive Officer at DEAR Health. DEARhealth targeted epilepsy because it is one of the many chronic and mental health conditions that, according to the Centers for Disease Control and Prevention, make up 90% of annual health care expenditures in the U.S. And while about 1-in-26 Americans will experience epilepsy at some point in their lives, many still suffer due to misconceptions and stigma surrounding their condition.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Monday, July 01


News

Rotigotine Transdermal Patches Market 2019 – UCB, … – Market Trends

UCB

Report represents a comprehensive study of theRotigotine Transdermal Patches Market. Get Free Sample Copy of Report Here : https://www.glamresearch.com/report/global-rotigotine-transdermal-patches-market-by-product-type–65076/#sample. Global Rotigotine Transdermal Patches Market: Type Segment Analysis 1mg 2mg 3mg 4mg 6mg 8mg. It gives overall idea about the market in terms of segmentation, market potential, influential trends and the challenges that the market is facing • To provide detailed description of key players and their marketing strategies followed by press releases and relevant documents so as to get competitive analysis market understanding • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market • To offer detailed profiles of key players with regional analysis and focus on key rising opportunities and challenges faced by this market • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Read Full Details

Topics:
  • Business
  • Financial

Saturday, June 29


News

UCB (OTCMKTS:UCBJF) Stock Price Up 1.9% – Tech Know Bits

UCB

UCB (OTCMKTS:UCBJF) Stock Price Up 1.9% – Tech Know Bits. The stock traded as high as $80.55 and last traded at $80.55. Approximately 725 shares traded hands during trading, an increase of 47% from the average daily volume of 492 shares. Separately, Zacks Investment Research upgraded UCB from a “sell” rating to a “hold” rating in a research report on Thursday, May 2nd.

Read Full Details

Topics:
  • Business
  • Financial

Friday, June 28


News

Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU

UCB AMGN

"Together with Amgen we will seek a re-examination of the CHMP opinion. The re-examination process gives us the opportunity to clarify our position on the submitted data with the goal of making EVENITY available to postmenopausal women at high risk of fracture in the EU." EVENITY (romosozumab-aqqg) was approved by the U.S. Food and Drug Administration (FDA) in April 2019, for the treatment of osteoporosis in postmenopausal women at high risk for fracture.5 EVENITY is also approved in Japan and South Korea for the treatment of osteoporosis for women and men at high risk for fracture and in Canada for the treatment of osteoporosis for postmenopausal women at high risk for fracture.6,7,8. The anabolic effect of EVENITY wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered. In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENITYTM compared to those treated with alendronate. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. While Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation.

Read Full Details

Topics:
  • Business
  • Health

Thursday, June 27


News

Is The Nowcast Positive?:Ucb, The Belgium, (Euronext BE:UCB.BB) - Research On Mathematics

UCB

The bussiness of the Company Ucb (Euronext BE : UCB.BB) started at $72.04, while the Previous price remained at $72.16 and ended at $71.36 with the difference of $-0.8, with the percentage of -1.11%. Sell signals can be generated through a variety of techniques. It is a technical and important part to determine a stock’s current value and predicting future price movement. General, traders can enhance the responsiveness of a Moving Average by decreasing the period and smooth-out movements by increasing the period.

Read Full Details

Topics:
  • Business
  • Financial
News

Stem Cell Umbilical Cord Blood (UCB) – Industry Journal

UCB

The report elaborates contemporary market trends, dynamics, and growth-driving forces that can pose a deep influence on the market and its growth prospects. The report offers estimations of up to 2024 which will prompt market players to operate their Stem Cell Umbilical Cord Blood (UCB) businesses accordingly. The Stem Cell Umbilical Cord Blood (UCB) market has been performing robustly at both regional and global levels and is anticipated to exhibit better performance during the forecast period. Factors such as raw material affluence, technological advancements, economic stability, increasing disposable incomes, adept workforce availability, and briskly escalating demand for the Stem Cell Umbilical Cord Blood (UCB) boosting market growth.

Read Full Details

Topics:
  • Business
  • Financial

Monday, June 03


News

UCB S A/ADR (UCBJY) Raised to Buy at Goldman Sachs Group – Slater Sentinel

UCB

UCB S A/ADR (UCBJY) Raised to Buy at Goldman Sachs Group – Slater Sentinel. Goldman Sachs Group upgraded shares of UCB S A/ADR (OTCMKTS:UCBJY) from a neutral rating to a buy rating in a research report sent to investors on Thursday, The Fly reports. Shares of OTCMKTS:UCBJY opened at $38.09 on Thursday. UCB S A/ADR has a 1-year low of $37.45 and a 1-year high of $46.69.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, May 28


News

UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration

UCB

We believe that inhibition of alpha-synuclein misfolding and oligomerization with an orally active, brain penetrant, small molecule represents a potential advantage over antibody therapeutics that are currently in development,” stated Errol De Souza, President and CEO of Neuropore Therapies. As announced in January 2015, Neuropore Therapies granted UCB a world-wide license to develop and commercialize alpha-synuclein targeting molecules in all indications. As a result of the milestone achieved with UCB0599, Neuropore will have cumulatively received $43 million of the potential $460 million in total milestones through its collaboration with UCB. Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease. Current treatments for PD are effective at managing the early motor symptoms of the disease, mainly through the use of levodopa and dopamine agonists. As the disease progresses and dopaminergic neurons continue to be lost, these drugs eventually become less effective at treating the symptoms. Neuropore possesses a pipeline with two therapeutic candidates in clinical development, UCB0599 and NPT520-34, In addition, Neuropore is developing several other small molecule programs that are in lead optimization and/or preclinical development. For more information visit www.neuropore.com. Forward looking statements.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial